Project – Prevalence of Extended-Spectrum Beta-Lactamase-Producing Enterobacterales: Clinical Bacterial Isolates from Selected Diagnostic Laboratories in Owerri, Imo State.

CHAPTER ONE

INTRODUCTION

1.1 Background to the Study

Antimicrobial resistance (AMR) has become one of the major public health challenges confronting healthcare systems worldwide because it reduces the effectiveness of medicines used to prevent and treat infectious diseases. Bacterial infections that were previously managed successfully with commonly prescribed antibiotics are increasingly becoming difficult to treat, resulting in prolonged illness, increased healthcare expenditure, longer hospital stays and a greater risk of death. The World Health Organization (WHO, 2024) identifies antimicrobial resistance as a serious threat to global health and emphasizes the importance of surveillance, infection prevention and control, appropriate antimicrobial use and the development of effective treatment options. The WHO’s Bacterial Priority Pathogens List 2024 also identifies third-generation cephalosporin-resistant Enterobacterales as a critical-priority group, highlighting the urgent need to address resistant bacterial pathogens. These developments demonstrate the importance of investigating antibiotic-resistant organisms through diagnostic laboratories, where clinical specimens can be examined to establish bacterial identity and resistance patterns. Consequently, determining the prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales is an important step towards understanding the burden of antibiotic resistance and improving the management of bacterial infections.

Enterobacterales are a large order of Gram-negative bacteria that includes clinically important organisms such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae complex, Citrobacter species, Proteus species and Serratia species. Some members of this group are normal inhabitants of the human gastrointestinal tract, while others can cause infections when they enter normally sterile body sites or affect individuals whose immune defences are compromised. These organisms are associated with urinary tract infections, bloodstream infections, wound infections, intra-abdominal infections and some respiratory infections. Their clinical importance is increased by their ability to acquire and spread resistance determinants that reduce the effectiveness of available antibiotics. The World Health Organization (WHO, 2024) recognizes resistant Enterobacterales as a major concern because of the severity of infections they can cause and the limited treatment options available when resistance becomes extensive. The clinical significance of these bacteria makes their isolation and identification in diagnostic laboratories essential for guiding appropriate treatment. Studying clinical bacterial isolates in selected laboratories in Owerri, Imo State, will therefore provide information on the organisms encountered in routine diagnostic practice and the extent to which they exhibit the ESBL-producing phenotype.

Extended-spectrum beta-lactamases are enzymes produced by certain bacteria that can break down and inactivate many beta-lactam antibiotics, particularly penicillins, extended-spectrum cephalosporins and aztreonam. Their activity can compromise the effectiveness of antibiotics such as cefotaxime, ceftriaxone and ceftazidime, depending on the particular enzyme and the organism involved. Common ESBL families include CTX-M, TEM and SHV variants, although not every member of the TEM or SHV families possesses an extended-spectrum phenotype. Many ESBL genes are carried on plasmids, which are mobile genetic elements capable of facilitating the spread of resistance determinants between bacteria. This transfer contributes to the dissemination of antibiotic resistance within healthcare environments and communities. Paterson and Bonomo (2005) explained the clinical importance of ESBLs, including their impact on antimicrobial susceptibility and the challenges they create for effective infection management. Similarly, Bush and Bradford (2020) described the continuing evolution of beta-lactamases and their implications for antibiotic treatment. Understanding these resistance mechanisms is fundamental to the present study because identifying ESBL-producing isolates will help establish the proportion of examined Enterobacterales that may be resistant to important beta-lactam antibiotics.

Infections caused by ESBL-producing Enterobacterales present significant clinical challenges because commonly used antibiotics may be ineffective even when the infecting organism belongs to a bacterial species that is ordinarily treatable with those medicines. Such infections may lead to delayed initiation of effective therapy, treatment failure, recurrent infection and prolonged hospitalization, particularly in patients with severe infections or underlying medical conditions. In bloodstream infections, delays in administering an effective antibiotic can be especially dangerous because the infection may progress to sepsis and organ dysfunction. Tamma et al. (2022), in their guidance on the treatment of antimicrobial-resistant Gram-negative infections, emphasized the need to use reliable microbiological identification and antimicrobial susceptibility results to inform treatment decisions. The WHO (2024) also highlights the importance of addressing resistant Gram-negative pathogens through effective diagnosis, infection prevention and appropriate antimicrobial treatment. These concerns demonstrate that ESBL production is not merely a laboratory finding but a resistance characteristic with direct implications for patient care. Establishing the prevalence of ESBL-producing Enterobacterales among clinical isolates from selected diagnostic laboratories in Owerri may provide useful evidence for clinicians, laboratory scientists and healthcare administrators seeking to strengthen the diagnosis and management of bacterial infections.

The burden of antimicrobial resistance varies across geographical regions because of differences in antibiotic consumption, healthcare access, infection prevention practices, diagnostic capacity and the circulation of resistant bacterial strains. Resistance may be particularly difficult to control where antibiotics are used without appropriate laboratory guidance, antimicrobial stewardship programmes are weak, or surveillance systems do not adequately capture local resistance patterns. The WHO (2024) emphasizes that antibiotic-resistant pathogens require regionally appropriate responses because their distribution and public health effects differ between settings. Murray et al. (2022), in a comprehensive global analysis of bacterial antimicrobial resistance, estimated that bacterial AMR was associated with 4.95 million deaths in 2019, including 1.27 million deaths directly attributable to bacterial resistance. These estimates concern bacterial AMR broadly rather than ESBL-producing Enterobacterales alone, but they illustrate the scale of the wider problem in which ESBL resistance occurs. For countries such as Nigeria, where healthcare facilities serve populations with differing access to diagnostic and treatment services, local evidence is important for identifying priority pathogens and guiding the use of available antibiotics. Research on ESBL-producing Enterobacterales in Owerri will contribute geographically specific information that can support a better understanding of resistance in the study setting.

Nigeria faces important challenges in controlling antimicrobial resistance, including the need to improve access to reliable diagnostic services, promote appropriate antibiotic prescribing and strengthen surveillance of resistant microorganisms. The clinical importance of ESBL-producing organisms is particularly evident in infections caused by E. coli and K. pneumoniae, which are frequently associated with urinary tract infections, bloodstream infections and other healthcare-related infections. Resistance to third-generation cephalosporins can complicate the treatment of these infections and increase dependence on alternative antibiotics, which may be more expensive, less accessible or associated with additional clinical considerations. The WHO (2024) places third-generation cephalosporin-resistant Enterobacterales among its critical-priority pathogens, reinforcing the importance of monitoring resistance in countries where the burden of resistant infections and limitations in healthcare resources may interact. Nevertheless, national or international findings cannot automatically be applied to every Nigerian state, city or laboratory because the prevalence of resistance may differ according to patient populations, specimen types, prescribing practices and laboratory methods. It is therefore necessary to generate local evidence rather than assume that findings from other geographical settings accurately represent the situation in Owerri, Imo State.

Diagnostic laboratories play an essential role in identifying bacterial pathogens and detecting antimicrobial resistance through culture, organism identification and antimicrobial susceptibility testing. When appropriate phenotypic methods are used, suspected ESBL-producing isolates can be assessed and confirmed according to established laboratory standards, such as the relevant procedures and interpretive criteria provided by the Clinical and Laboratory Standards Institute (CLSI). Reliable laboratory procedures are necessary because resistance patterns cannot be determined accurately from clinical symptoms alone, and screening results should not be treated as equivalent to confirmed ESBL production. The WHO (2024) emphasizes the importance of surveillance and laboratory capacity in responding to antimicrobial resistance, while Paterson and Bonomo (2005) demonstrate the clinical significance of accurately recognizing ESBL-producing bacteria. In Owerri, examining clinical bacterial isolates from selected diagnostic laboratories will make it possible to estimate the proportion of eligible Enterobacterales isolates that produce ESBLs, identify the bacterial species most frequently associated with ESBL production and describe their distribution across specimen types and other relevant characteristics. The findings may provide a baseline for future surveillance, support evidence-based antimicrobial stewardship and inform infection prevention strategies. Accordingly, this study seeks to determine the prevalence of ESBL-producing Enterobacterales among clinical bacterial isolates obtained from selected diagnostic laboratories in Owerri, Imo State.

1.2 Statement of the Problem

The increasing occurrence of antibiotic-resistant bacterial infections presents a serious challenge to effective healthcare delivery, particularly when commonly prescribed antibiotics are no longer capable of controlling the organisms responsible for infection. ESBL-producing Enterobacterales are of particular concern because the enzymes they produce can inactivate several important beta-lactam antibiotics, including many third-generation cephalosporins. This resistance can complicate treatment decisions, delay the administration of effective therapy and increase the risk of adverse clinical outcomes. The World Health Organization (WHO, 2024) classifies third-generation cephalosporin-resistant Enterobacterales as critical-priority pathogens, demonstrating the public health importance of resistance within this bacterial group. Despite the increasing recognition of this threat, effective control requires reliable information about the organisms circulating in particular healthcare settings. Without adequate laboratory-based surveillance, healthcare professionals may have limited evidence for determining the likely burden of ESBL-producing bacteria and selecting appropriate empirical antibiotic treatment.

A second problem concerns the variation in the prevalence of ESBL-producing Enterobacterales across hospitals, communities, geographical regions and clinical specimen types. Findings from one location may not accurately represent another because resistance patterns are influenced by antibiotic exposure, infection prevention practices, patient characteristics and the circulation of resistant bacterial strains. Murray et al. (2022) demonstrated the substantial global burden associated with bacterial antimicrobial resistance, while Bush and Bradford (2020) explained how the diversity and evolution of beta-lactamases continue to complicate antibiotic treatment. Although these studies establish the broader importance of resistance, they do not determine the prevalence of ESBL-producing Enterobacterales in the selected diagnostic laboratories in Owerri, Imo State. Consequently, relying exclusively on global estimates or results from other parts of Nigeria may provide an incomplete picture of the local situation.

Another problem is the potential limitation of routine diagnostic information when laboratory findings are not systematically analysed to establish the frequency and distribution of ESBL-producing organisms. Bacterial culture and routine antimicrobial susceptibility testing are important for patient management, but a study specifically investigating ESBL prevalence requires suitable screening and confirmation procedures. The Clinical and Laboratory Standards Institute (CLSI, 2024) provides standardized guidance for antimicrobial susceptibility testing, while Paterson and Bonomo (2005) emphasize the clinical significance of correctly identifying ESBL-producing organisms. Where data on confirmed ESBL production are unavailable, incomplete or not systematically compiled, it becomes difficult to establish which bacterial species contribute most to the observed burden and which specimen types yield the highest proportion of positive isolates. This creates a need for a structured investigation using appropriate laboratory methods and clearly defined inclusion criteria.

The central problem addressed by this study is the absence of a study-specific, systematically established estimate of the prevalence of ESBL-producing Enterobacterales among eligible clinical bacterial isolates obtained from the selected diagnostic laboratories in Owerri, Imo State. Without such evidence, it may be difficult to assess the magnitude of the problem within the study population, identify the bacterial species most frequently associated with ESBL production and describe the distribution of positive isolates according to specimen type and relevant patient characteristics. Tamma et al. (2022) highlight the importance of microbiological evidence in guiding the treatment of antimicrobial-resistant Gram-negative infections, while the WHO (2024) emphasizes the need for effective surveillance to inform public health responses. This study will therefore investigate the prevalence of ESBL-producing Enterobacterales in selected diagnostic laboratories in Owerri, generating local evidence that may contribute to improved surveillance, appropriate antibiotic use and better-informed infection prevention practices.

1.3 Aim and Objectives of the Study

1.3.1 Aim of the Study

The aim of this study is to determine the prevalence of extended-spectrum beta-lactamase-producing Enterobacterales among clinical bacterial isolates obtained from selected diagnostic laboratories in Owerri, Imo State.

1.3.2 Specific Objectives

The specific objectives are to:

1. Determine the prevalence of ESBL-producing Enterobacterales among eligible clinical bacterial isolates obtained from selected diagnostic laboratories in Owerri, Imo State.

2. Identify the Enterobacterales species most frequently associated with ESBL production among the clinical isolates examined.

3. Determine the distribution of ESBL-producing Enterobacterales according to clinical specimen type, such as urine, blood, wound swabs and other eligible specimens.

4. Assess the antimicrobial susceptibility patterns of ESBL-producing Enterobacterales to selected antibiotics using appropriate laboratory methods and applicable interpretive standards.

1.4 Research Questions

The study will answer the following research questions:

1. What is the prevalence of ESBL-producing Enterobacterales among eligible clinical bacterial isolates from selected diagnostic laboratories in Owerri, Imo State?

2. Which Enterobacterales species are most frequently associated with ESBL production among the isolates examined?

3. How are ESBL-producing Enterobacterales distributed across different clinical specimen types?

4. What are the antimicrobial susceptibility patterns of the ESBL-producing Enterobacterales against the selected antibiotics tested?

1.5 Research Hypotheses

The following null hypotheses will guide the inferential aspects of the study, where applicable.

H₀₁: There is no statistically significant difference in the prevalence of ESBL production among the Enterobacterales species examined.

H₀₂: There is no statistically significant association between clinical specimen type and ESBL production among the eligible Enterobacterales isolates.

H₀₃: There is no statistically significant association between the selected patient characteristics and ESBL production, where relevant patient data are available.

H₀₄: There is no statistically significant difference in the observed susceptibility patterns of ESBL-producing Enterobacterales across the selected antibiotics tested.

Note: The final choice of statistical tests and hypotheses should reflect the actual study design, sample size, available patient information and laboratory results. In particular, comparisons of antibiotic susceptibility should account for the fact that results from multiple antibiotics tested against the same isolate are not necessarily independent.

1.6 Significance of the Study

The findings of this study are expected to be beneficial to healthcare professionals, medical laboratory scientists, patients, diagnostic laboratories, public health authorities and future researchers.

1.6.1 Healthcare Professionals

The study may provide clinicians with useful local information on the prevalence of ESBL-producing Enterobacterales and the bacterial species most frequently associated with this resistance mechanism. Such information may support informed empirical treatment decisions while awaiting laboratory results. Tamma et al. (2022) emphasize the importance of microbiological evidence and appropriate antibiotic selection in managing antimicrobial-resistant Gram-negative infections. The findings may therefore help healthcare professionals recognize the importance of obtaining appropriate specimens and requesting microbiological investigations when resistant bacterial infections are suspected.

1.6.2 Medical Laboratory Scientists

The study may strengthen awareness of the importance of standardized laboratory procedures for detecting ESBL production. By examining bacterial identification, ESBL screening and confirmation, and antimicrobial susceptibility patterns, the research may encourage the consistent application of appropriate laboratory standards. CLSI (2024) provides guidance on antimicrobial susceptibility testing, which is important for producing reliable and clinically interpretable results. The findings may also provide a basis for improving laboratory documentation and the systematic reporting of resistant organisms.

1.6.3 Patients and the General Public

Patients may benefit indirectly from improved awareness of the local burden of antibiotic-resistant infections and the importance of appropriate antibiotic use. When resistance information is available and used appropriately, healthcare professionals may be better positioned to select effective treatment and reduce avoidable exposure to ineffective antibiotics. The WHO (2024) identifies surveillance, effective diagnosis and responsible antimicrobial use as important components of antimicrobial resistance control. The study may consequently contribute to broader efforts to improve patient safety and encourage responsible antibiotic use.

1.6.4 Diagnostic Laboratories in Owerri

The selected diagnostic laboratories may benefit from having documented evidence of the occurrence and distribution of ESBL-producing Enterobacterales among the eligible isolates examined. The results may assist laboratory managers in identifying areas requiring improved resistance surveillance, reviewing laboratory procedures and strengthening communication of clinically significant resistance findings. The findings may also provide baseline data for subsequent investigations and comparisons, provided that similar sampling methods and laboratory standards are used.

1.6.5 Public Health Authorities

Public health authorities and antimicrobial stewardship programme coordinators may use the findings as locally generated evidence when planning interventions to reduce antibiotic resistance. Bush and Bradford (2020) explain the continuing challenges created by the diversity of beta-lactamases, while the WHO (2024) emphasizes the need for locally appropriate strategies to control resistant pathogens. Although a study involving selected laboratories cannot establish the prevalence for the entire population of Imo State, it may contribute useful information to wider surveillance and public health planning.

1.6.6 Future Researchers and Academic Institutions

The study may serve as a reference for students and researchers interested in clinical microbiology, antimicrobial resistance, epidemiology and diagnostic laboratory practice. It may also identify research questions requiring further investigation, including the molecular characteristics of ESBL genes, transmission patterns and changes in resistance over time. Paterson and Bonomo (2005) provide an important foundation for understanding ESBL mechanisms, and subsequent local investigations may build on this knowledge by incorporating molecular characterization and larger multisite studies.

1.7 Scope of the Study

The study will focus on determining the prevalence of ESBL-producing Enterobacterales among eligible clinical bacterial isolates obtained from selected diagnostic laboratories in Owerri, Imo State.

The geographical scope will be limited to the selected diagnostic laboratories within the defined study area. The target population will comprise eligible clinical Enterobacterales isolates recovered from specimens submitted for routine diagnostic investigation during the specified study period. The final number of laboratories, sample size and duration of data collection will be established in the methodology chapter.

The laboratory scope will include the identification of relevant Enterobacterales, screening and confirmation of ESBL production using appropriate phenotypic methods, and assessment of antimicrobial susceptibility to selected antibiotics. Laboratory procedures and interpretations will follow the applicable CLSI standards or other explicitly specified validated standards.

The study will also examine the distribution of ESBL-producing isolates by bacterial species and clinical specimen type. Patient characteristics, such as age and sex, may be assessed where ethically approved and reliably available. Molecular detection of ESBL genes will not be included unless specifically incorporated into the research design and supported by the necessary laboratory facilities.

The findings will apply primarily to the eligible isolates obtained from the selected laboratories and should not automatically be generalized to all patients, healthcare facilities or residents of Imo State.

1.8 Limitations of the Study

The study may encounter limitations associated with the availability of eligible clinical isolates, incomplete laboratory records, financial constraints and access to laboratory reagents. Differences in the diagnostic practices of participating laboratories may also affect the comparability of the data if appropriate standardized procedures are not maintained.

Furthermore, a study based on selected diagnostic laboratories may not represent the full burden of ESBL-producing Enterobacterales in the wider community. Patients whose infections are not investigated by the selected laboratories will not be represented in the study population. Where molecular testing is not performed, the study will establish phenotypically confirmed ESBL production but will not identify the specific resistance genes responsible.

These limitations can be minimized through clearly defined inclusion and exclusion criteria, appropriate quality-control procedures, standardized data collection and transparent reporting of the sampling method. The limitations will be acknowledged when interpreting the findings.

1.9 Operational Definition of Terms

Antimicrobial resistance: The ability of a microorganism to survive or grow despite exposure to an antimicrobial agent that would ordinarily inhibit or kill it.

Enterobacterales: An order of Gram-negative bacteria that includes clinically important genera such as Escherichia, Klebsiella, Enterobacter, Citrobacter, Proteus and Serratia.

Extended-spectrum beta-lactamases (ESBLs): Enzymes produced by certain bacteria that hydrolyse and inactivate many penicillins, extended-spectrum cephalosporins and aztreonam.

ESBL-producing Enterobacterales: Enterobacterales isolates that demonstrate ESBL production according to the screening and confirmation criteria adopted for the study.

Clinical bacterial isolates: Bacterial organisms recovered from clinical specimens submitted to the selected diagnostic laboratories for microbiological investigation.

Prevalence: The proportion of eligible Enterobacterales isolates examined during the study period that are confirmed to produce ESBLs, expressed as a percentage.

Antimicrobial susceptibility testing: Laboratory procedures used to determine whether a bacterial isolate is susceptible, susceptible with increased exposure, or resistant to particular antimicrobial agents, according to the interpretive standard adopted.

Clinical specimen: Material collected from a patient, such as urine, blood, pus or a wound swab, for diagnostic laboratory examination.

Diagnostic laboratory: A laboratory that receives and examines clinical specimens to identify microorganisms and provide information relevant to disease diagnosis and treatment.

Owerri, Imo State: The geographical study area in southeastern Nigeria in which the selected diagnostic laboratories are located.

Project – Prevalence of Extended-Spectrum Beta-Lactamase-Producing Enterobacterales: Clinical Bacterial Isolates from Selected Diagnostic Laboratories in Owerri, Imo State.